Fore Biotherapeutics



HBM contact: Dr Chandra P. Leo

Company status: private

Fore Biotherapeutics (former Novellus) is a biotechnology company developing compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Fore Biotherapeutics’ lead program, PLX-8394, is in clinical development for BRAF-mutated tumors without approved therapies.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171